← Back to Clinical Trials
Recruiting NCT06877312

NCT06877312 Longitudinal Study to Investigate Different Transcranial Electrical Stimulation

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06877312
Status Recruiting
Phase
Sponsor University of Manitoba
Condition Dementia; Degenerative, Dementia Mixed
Study Type INTERVENTIONAL
Enrollment 200 participants
Start Date 2024-10-09
Primary Completion 2030-12-31

Eligibility & Interventions

Sex All sexes
Min Age 50 Years
Max Age 95 Years
Study Type INTERVENTIONAL
Interventions
Transcranial Direct Current Stimulation (tDCS)30 Hz Transcranial Alternating Current Stimulation (tACS)50 Hz Transcranial Alternating Current Stimulation (tACS)

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 200 participants in total. It began in 2024-10-09 with a primary completion date of 2030-12-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This research investigates the effect of different frequencies of tACS (0 Hz, 30 Hz, 50 Hz, 70 Hz, 90 Hz) and tRNS with cognitive exercises in a regimen protocol of 4 weeks, everyday (Monday to Friday). The study design is a longitudinal study design in which participants receive different tES randomly ordered. Treatments occur for 4 weeks, then 12 weeks of no treatment (wash-out period), repeated for each tES treatment type. Participants have the option of having their choice of music in the background while they perform cognitive exercises.

Eligibility Criteria

Inclusion Criteria: * ability to read, write and speak English fluently * MoCA score between 5 and 24 Exclusion Criteria: * Being diagnosed with Parkinson's disease, Parkinsonian dementia, Huntington disease, speech significant aphasia and intellectual disability, major depression/anxiety, bipolar disorder, schizophrenia or any other major mood disorder. * Having a history of epileptic seizures or epilepsy * Inability to adequately communicate in English * Impaired vision or hearing severe enough to impair performance in cognitive tests * Current substance abuse disorder * Currently participating in another therapeutic study for dementia * Plan to change the medication during any treatment period (5 weeks including the pre-post assessments)

Contact & Investigator

Central Contact

Shelly Rempel-Rossum

✉ Shelly.rempelrossum@umanitoba.ca

📞 204-789-3389

Frequently Asked Questions

Who can join the NCT06877312 clinical trial?

This trial is open to participants of all sexes, aged 50 Years or older, up to 95 Years, studying Dementia; Degenerative, Dementia Mixed. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06877312 currently recruiting?

Yes, NCT06877312 is actively recruiting participants. Contact the research team at Shelly.rempelrossum@umanitoba.ca for enrollment information.

Where is the NCT06877312 trial being conducted?

This trial is being conducted at Winnipeg, Canada.

Who is sponsoring the NCT06877312 clinical trial?

NCT06877312 is sponsored by University of Manitoba. The trial plans to enroll 200 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology